Abstract
Most therapies target proliferating tumor cells, resulting in tumor debulking. However, frequently drug-resistant, residual tumor cells are present and are thought to be responsible for tumor recurrence and patient mortality. Significant data points to the fact that tumors are heterogeneous, being composed of proliferative and nonproliferating tumor cell subpopulations. Frequently, the latter is therapy-resistant and exhibits cancer stem-like properties. Glucose Regulated Protein of 78kDa (GRP78) has been implicated in both drug resistance and in stem-like cell behaviors, and has been shown to be a targetable cell surface receptor. Specifically, antibodies binding to the carboxyl terminus of GRP78 induce tumor cell death by inhibiting the Akt pathway. Collectively, this knowledge underscores the importance of developing combination therapies that target both proliferating populations and nonproliferating drug-resistant tumor cell subpopulations. Moreover, this collective work identifies cell surface GRP78 as a promising therapeutic target on the cell surface of therapy-resistant tumor cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Cell Surface GRP78, a New Paradigm in Signal Transduction Biology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
